Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings
暂无分享,去创建一个
D. Catovsky | A. Wotherspoon | A. Gruszka-Westwood | E. Matutes | J. Swansbury | M. Scully | R. Morilla | T. Min | B. Hilditch | S. Atkinson | C. Alvares | Benjamin L Hilditch
[1] E. Jaffe. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .
[2] J. Strauchen. Primary bone marrow B-cell lymphoma: report of four cases. , 2003, The Mount Sinai journal of medicine, New York.
[3] A. Zelenetz,et al. Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. , 2002, Blood.
[4] D. Hossfeld. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .
[5] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[6] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[7] R. Fonseca,et al. Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization , 2001, British journal of haematology.
[8] W. Chan,et al. New approaches to lymphoma diagnosis. , 2001, Hematology. American Society of Hematology. Education Program.
[9] M. Dyer,et al. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. , 2000, Blood.
[10] F. Berger,et al. CDK1 and cyclin A expression is linked to cell proliferation and associated with prognosis in non-Hodgkin's lymphomas. , 1999, Leukemia & lymphoma.
[11] L. Kearney,et al. The impact of the new FISH technologies on the cytogenetics of haematological malignancies , 1999, British journal of haematology.
[12] S. Korsmeyer. BCL-2 gene family and the regulation of programmed cell death. , 1995, Cancer research.
[13] Philippe Dessen,et al. A database on cytogenetics in haematology and oncology , 1999, Nucleic Acids Res..
[14] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[15] R. Gascoyne. Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Hematology/oncology clinics of North America.
[16] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[17] D. Weisenburger,et al. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.